Among the ESCRT-III components, mutations in the Chmp2B gene are reported to be associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) [64], which provides a clear link between dysfunction in the ESCRT-III machinery and neurodegeneration. This evidence concerns the gene CHMP2B and amyotrophic lateral sclerosis.